Alnylam Pharmaceuticals revenue and financials

ALNY · NASDAQ · USD

$223.94+1.84%+$4.05

Close · October 6, 2026

In the fiscal year ended December 2025, Alnylam Pharmaceuticals reported revenue of $3.71B (+65.19% year over year). Net income was $313.75M, a net margin of 8.4%.

Annual revenue · 2025: $3.71B

$89.91M2017
$2.9M2017
$74.91M2018
$219.75M2019
$492.85M2020
$844.29M2021
$1.04B2022
$1.83B2023
$2.25B2024
$3.71B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +65.19%; 2025 vs 2024
Net margin: 8.4%; 2024: -12.4%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total assets	5,559	5,130	4,966	4,852	4,566	4,214	4,240	4,205	4,010	3,824	3,830	3,839
Current assets	4,620	4,219	4,051	3,953	3,644	3,268	3,295	3,355	3,173	2,989	2,983	2,985
Cash and equivalents	1,708	1,711	1,657	1,490	1,114	1,020	966	1,100	968	682	813	1,033
Short-term investments	1,600	1,298	1,251	1,234	1,744	1,613	1,728	1,680	1,656	1,689	1,627	1,373
Receivables	913	884	778	965	567	418	405	354	309	321	328	325
Inventory	97.1	84.0	82.7	75.4	71.7	65.6	78.5	76.0	84.0	94.0	89.1	95.8
Net property, plant and equipment	738	708	708	693	692	696	694	703	715	719	726	729
Current liabilities	1,513	1,349	1,466	1,555	1,301	1,076	1,186	1,221	1,055	942	968	950
Accounts payable	108	127	116	118	102	97.4	88.4	70.8	74.0	78.1	55.5	73.8
Long-term debt	2,472	2,479	2,478	2,389	2,372	2,364	2,359	2,358	2,365	2,359	2,343	2,331
Total debt	1,267	1,273	1,278	1,308	1,297	—	—	—	—	—	—	—
Total liabilities	4,205	4,054	4,177	4,618	4,315	4,098	4,173	4,173	4,013	4,044	4,051	4,005
Total equity (incl. minority)	1,354	1,075	789	234	251	115	67.1	32.4	-3.1	-219	-221	-166
Retained earnings	-6,332	-6,497	-6,703	-7,160	-7,412	-7,345	-7,288	-7,204	-7,092	-7,076	-7,010	-6,872